Myriad Genetics, Inc.

MYGN

US62855J1043

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq Other stock markets 04:00:00 2025-01-16 pm EST			5-day change	1st Jan Change
12.52 ^USD	-4.79%		-15.29%	-8.68%

Jan. 15	Myriad Genetics, Inc. Presents at 43rd Annual J.P. Morgan Healthcare Conference 2025, Jan-15-2025 03:45 PM
Jan. 15	Myriad Genetics Expects Higher Q4 Revenue, Provides 2025 Guidance	MT

Myriad Genetics, Ultima Genomics Collaborate to Explore UG 100 Sequencing Platform

October 03, 2024 at 12:34 pm EDT

This article is reserved for members

Already a member?

Not a member ?

Free registration

Latest news about Myriad Genetics, Inc.

Myriad Genetics, Inc. Presents at 43rd Annual J.P. Morgan Healthcare Conference 2025, Jan-15-2025 03:45 PM	Jan. 15
Myriad Genetics Expects Higher Q4 Revenue, Provides 2025 Guidance	Jan. 15	MT
(MYGN) Myriad Genetics Expects Fiscal Year 2025 Adjusted EPS Range $0.07 - $0.11	Jan. 15	MT
(MYGN) Myriad Genetics Expects Fiscal Year 2025 Revenue Range $840M - $860M	Jan. 15	MT
Myriad Genetics, Inc. Provides Unaudited Earnings Guidance for the Fourth Quarter and Full-Year Ended December 31, 2024 and Full-Year of 2025	Jan. 15	CI
Myriad Genetics, Inc. Provides Impairment Guidance for the Fourth Quarter and Full Year Ended December 31, 2024	Jan. 15	CI
Myriad Genetics Forms 5-Year Alliance With MD Anderson to Evaluate Molecular Residual Disease Assay	Jan. 07	MT
Myriad Genetics, Inc.(NasdaqGS:MYGN) dropped from NASDAQ Biotechnology Index	Dec. 19	CI
Top Premarket Decliners	Dec. 12	MT
Myriad Genetics Expects to Reach Resolution With UnitedHealthcare Over Pharmacogenetic Testing Before Yearend	Dec. 11	MT
Myriad Genetics Elects Mark S. Davis as New Board Member	Dec. 10	CI
Leerink Partners Downgrades Myriad Genetics to Market Perform From Outperform, Cuts Price Target to $21 From $30	Dec. 09	MT
Myriad Genetics, Inc. Announces Updates to Its Agreement with Illumina Inc	Nov. 20	CI
Sintx Technologies, Inc. Appoints Gregg R. Honigblum as Chief Strategy Officer	Nov. 19	CI
Morgan Stanley Cuts Price Target on Myriad Genetics to $21 From $32, Keeps Equalweight Rating	Nov. 18	MT
Myriad Genetics Says Fetal Gender Test Available at Over 8,000 Stores in US	Nov. 13	MT
Myriad Genetics, Inc. Expands Access to At-Home Early Fetal Sex DNA Test with Retail Launch	Nov. 13	CI
(MYGN) MYRIAD GENETICS Forecasts Fiscal Year 2024 EPS Range $0.12 - $0.14	Nov. 07	MT
Earnings Flash (MYGN) MYRIAD GENETICS Posts Q3 EPS $0.06	Nov. 07	MT
Earnings Flash (MYGN) MYRIAD GENETICS Reports Q3 Revenue $213M	Nov. 07	MT
Myriad Genetics, Inc., Q3 2024 Earnings Call, Nov 07, 2024	Nov. 07
Myriad Genetics, Inc. Reports Impairment Charges for the Third Quarter Ended September 30, 2024	Nov. 07	CI
Myriad Genetics, Inc. Revises Earnings Guidance for the Year 2024	Nov. 07	CI
Myriad Genetics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024	Nov. 07	CI
Myriad Genetics in Active Talks with UnitedHealthcare to Keep Coverage of GeneSight	Nov. 04	DJ

Myriad Genetics, Inc. is a genetic testing and precision medicine company. The Company develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. The Company is focused on three key areas where it has specialized products, capabilities, and expertise: Oncology, Women's Health and Mental Health. In oncology, it offers testing for patients who have cancer and companion diagnostic tests that work with corresponding drugs and treatments. It also offers the SneakPeek Early Gender DNA Test which can reveal a baby's gender as early as six weeks into pregnancy. The Companyâs testing products include MyRisk, BRACAnalysis, BRACAnalysis CDx, MyChoice CDx, Prolaris, Foresight, Prequel, Precis Tumor Test, Precise Liquid Test, SneakPeek and GeneSight, among others.

Employees

2,700

Sector

Medical Equipment, Supplies & Distribution

Calendar

2025-03-03 - Q4 2024 Earnings Release (Projected)

More about the company